Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
DaxibotulinumtoxinA for Injection (DAXI; Revance Therapeutics, Inc., Newark, CA) represents the first truly differentiated botulinum toxin formulation in the United States, the only type A botulinum toxin (BoNTA) wholly manufactured in the United States, and the first to be formulated…
Summary and key features Neuronox® is the botulinum toxin type A (BoNT-A) product most similar to Botox® in terms of formulation, molecular composition, pharmacodynamics, and clinical performance. Innotox® is the first ready-to-use liquid type BoNT-A product, with no animal-derived materials…
Summary and key features Botulinum neurotoxin E is one of seven botulinum neurotoxin serotypes. Botulinum neurotoxin E has the fastest onset and shortest duration of action compared to any of the botulinum neurotoxin serotypes. Botulinum neurotoxin E is not currently…
Summary and key features BTXB is believed to have an increased radius of diffusion when compared with BTXA Rate of onset of BTXB is increased over BTXA Although dose-dependent, the duration of BTXB effect has not been shown to be…
Summary and key features Prabotulinum toxin A is a 900 kDa botulinum toxin type A that was approved for use in the United States in 2019 for the treatment of glabellar lines. Prabotulinum toxin A has since been similarly approved…
Summary and key features IncobotulinumtoxinA (NT 201, Xeomin™, Bocouture ™) is an effective and well-tolerated treatment for facial wrinkles that is approved for the treatment of glabellar frown lines, lateral periorbital lines (crow’s feet) and upper facial lines in many…
Summary and key features Abobotulinumtoxin (AboBoNT) is a botulinum toxin A with similar features to the other type A botulinum toxins. The accessory proteins that surround the neurotoxin protein are already dissociated in the vial after reconstitution. Is “diffusion” an…
Summary and key features In 2002 BOTOX® Cosmetic (onabotulinumtoxinA) became the first botulinum neurotoxin FDA approved for the management of facial lines, introducing a new chapter in aesthetic dermatology. Following local injection into muscles, onabotulinumtoxinA inhibits the release of acetylcholine…
Summary and key features In the mid-1980s Dr. Jean Carruthers noticed a concomitant improvement in glabellar rhytides in a patient treated with botulinum toxin (BoNT-A) for blepharospasm. The first trial involved 18 patients and was published in 1992. By 2002,…
Summary and key features Botulinum neurotoxin type A (BoNT/A) was first used clinically for the ophthalmic conditions of strabismus and blepharospasm. Over the years, the number of medical conditions for which BoNT/A is used has grown based on its local…